Real-world case · What fell short · Private valuation

IPEV 2025: a private-company mark is a documented judgement, not a market price

Why the 2025 IPEV guidelines matter for fund NAV, how calibration and instrument rights change a mark, and which valuation shortcuts investors should challenge.

Outcome lensWhat fell short
EventGuidelines published 11 December 2025
Reading time11 minutes
Evidence review7 August 2026
Evidence status

The publication and fair-value framework are confirmed. Valuation examples are simplified illustrations.

The underwriting question

When no quoted price exists, what makes a private valuation defensible?

AssetsNest judgement

A defensible mark connects current operating evidence, market-participant assumptions and the exact instrument rights to a calibrated entry point. Consistency helps, but repeating last quarter's multiple without confronting new evidence is not valuation discipline.

Confirmed
11 Dec 2025

publication date

IPEV issued updated international private-capital valuation guidelines.

Confirmed
IFRS 13 / ASC 820

fair-value anchors

The guidelines are designed to be consistent with major fair-value accounting frameworks.

Illustrative
₹600m

common-equity bridge

A ₹1,000m enterprise value less ₹300m debt and ₹100m senior preference leaves ₹600m before other claims and dilution.

Why this case matters

A listed share receives an executable market price. A private fund receives a valuation committee meeting. Both numbers may be called value, but only one can normally be tested by selling a small amount today.

IPEV's updated guidelines matter because private marks feed reported NAV, fund performance, collateral tests, continuation transactions and sometimes compensation. The mark is therefore not harmless bookkeeping. It should leave an audit trail from instrument rights and entry calibration to current company evidence and market inputs.

Transaction chronology

What happened, and when the meaning changed

Price and security rights establish a calibration point.

The round price cannot be reused blindly if it reflected strategic terms, distress, bundled rights or a different capital class.

The valuer updates operating results, forecasts, market comparables and risk.

Method consistency is secondary to faithful use of current evidence.

IPEV published the updated guidelines.

The framework reinforced a market-participant view across private capital strategies.

A transaction provides a new calibration point.

Its price still requires adjustment for stake size, rights, compulsion and transaction context.

Economics and mechanics

Follow the claim, not the label

Calibrate, then explain the change

If an investment was priced at 12× EBITDA and a similar listed peer group later trades at 8×, retaining 12× needs specific offsetting evidence—perhaps faster growth, lower leverage or a contracted milestone. 'Private assets are long term' is not an input.

Enterprise value is not common equity

Deduct debt, add excess cash where available, then model preferred liquidation, accrued dividends, options and conversion. The latest round's preferred price can overstate common value when downside rights are material.

Illiquidity is not a plug

A discount for lack of marketability cannot rescue an inflated forecast. First value the business and security on coherent assumptions; then support any liquidity adjustment with holding period, transfer limits and market evidence.

Stakeholder ledger

Who gained flexibility—and who kept the risk?

GP and valuation committee

They select inputs and methods and must document judgements that can affect reported performance and fees.

LPs

They rely on marks for portfolio decisions but cannot necessarily convert them into cash on demand.

Lenders

NAV facilities may use marks in borrowing-base tests, turning valuation changes into covenant consequences.

Auditors and independent valuers

They challenge process and evidence but do not transform an estimate into an executable market quote.

Competing interpretations

The constructive reading

A transparent policy, independent challenge and frequent calibration produce decision-useful marks that respond to evidence without importing public-market noise mechanically.

The sceptical reading

Stale forecasts, selected comparables and unmodelled preferences keep NAV high, delaying recognition until a financing, covenant breach or sale forces the issue.

What the evidence cannot settle

Open questions and verification limits

  • No global guideline removes judgement or information asymmetry.
  • A third-party valuation is not automatically independent if scope, inputs and compensation are controlled by the manager.
  • A later sale can differ from prior fair value because conditions changed; difference alone does not prove misconduct.

Diligence lessons

What to carry into the next investment memo

  1. Ask what changed since entry and which observable input most contradicts the chosen mark.
  2. Rebuild the capital waterfall before accepting a per-share value.
  3. Track valuation-policy changes and overrides at the same level as the reported return.
  4. Keep realised cash, unrealised value and debt-funded distributions separate in performance reporting.

Source file

Sources are labelled by provenance. Company and provider claims remain attributed; illustrative calculations are not presented as observed results.

Institutional researchIPEV — 2025 Valuation GuidelinesOpen source ↗Read the AssetsNest research methodology
Important information

AssetsNest Investor Services — ARN 318691. This case study is educational and informational only. It is not personalised investment, legal or tax advice, an offer, a solicitation or a recommendation. Figures may be company-reported, institutionally estimated or illustrative as labelled. Verify current primary documents and seek appropriately qualified advice before acting.